Lipid-Lowering Therapy Guidelines / 대한내과학회지
Korean Journal of Medicine
;
: 396-402, 2019.
Article
in Korean
| WPRIM
| ID: wpr-938639
ABSTRACT
The major guidelines for lipid-lowering therapy (LLT) have been revised recently. Although “higher cardiovascular risk-aggressive LLT with greater absolute clinical benefit†is the main idea underlying all guidelines, there are some differences in the details among them. The US guidelines recommend pharmacological LLT based on a patient's risk category, independently of their low-density lipoprotein-cholesterol (LDL-C) level. However, the European and Korean guidelines consider the patient's risk category and LDL-C at the same time. Lifestyle modifications are suggested in parallel in all guidelines. The newest US guidelines have characteristically revived target LDL-C values in some patient groups and indications for non-statin drugs (ezetimibe and PCSK9 inhibitors), whereas the European and Korean guidelines have maintained target LDL-C values as usual. It is universally accepted that statins are the first-line agent. Adding ezetimibe, bile acid sequestrants, or PCSK9 inhibitors is recommended as a second line treatment. Appreciating the trend and background of the newest LLT guidelines will be essential to maximize cardiovascular prevention in patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Practice guideline
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS